Trial
NCT06680479
Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy
Phase ISUSPENDEDOTHER/UNKNOWNConfidence: LOW
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
Duke University; Access to Advanced Health Institute (AAHI)
Condition
HIV-1
Intervention
CH505 TF chTrimer
Why stopped
Temporarily Closed (paused)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-03